DZD3969
/ Dizal Pharmaceutical, AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 20, 2020
Assessing an Oral SERD, DZD3969 in Patients With Advanced ER+HER2- Breast Cancer (MU-LAN1)
(clinicaltrials.gov)
- P1/2; N=162; Not yet recruiting; Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
New P1/2 trial
1 to 1
Of
1
Go to page
1